Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05498220 · UNC Lineberger Comprehensive Cancer Center · PHASE2 · terminated · last registry update 2026-04-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding” | – | Registry record, UNC Lineberger Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD79B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Zilovertamab vedotin (NCT07917754)
- 2026-11-02Phase 3 first posted: AstraZeneca, Surovatamig + Rituximab (NCT07911553)
- 2026-10-28Results posted on the registry: Washington University School of Medicine, Mosunetuzumab + Polatuzumab vedotin (NCT05410418)
- 2026-05-13Results posted on the registry: University of Washington, Mosunetuzumab + Obinutuzumab (NCT05169658)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2025-12-22Results posted on the registry: Hoffmann-La Roche, Polatuzumab Vedotin + Rituximab (NCT04182204)
- 2025-10-03Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor + Rituximab (NCT04607772)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision